Free Trial
NASDAQ:ALDX

Aldeyra Therapeutics Q1 2024 Earnings Report

Aldeyra Therapeutics logo
$5.05 -0.04 (-0.79%)
Closing price 04:00 PM Eastern
Extended Trading
$5.06 +0.01 (+0.20%)
As of 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aldeyra Therapeutics EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.08
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Aldeyra Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aldeyra Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 2, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Aldeyra Therapeutics' Q2 2025 earnings is scheduled for Wednesday, July 30, 2025

Aldeyra Therapeutics Earnings Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Aldeyra Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aldeyra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aldeyra Therapeutics and other key companies, straight to your email.

About Aldeyra Therapeutics

Aldeyra Therapeutics (NASDAQ:ALDX) is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

View Aldeyra Therapeutics Profile

More Earnings Resources from MarketBeat